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Abstract 
Sildenafil is a phosphodiesterase 5 inhibitor widely used for the treatment of pulmonary hypertension in 
children. Despite limited available safety and efficacy evidence, use of sildenafil continues to increase. To 
date, sildenafil use for pediatric pulmonary hypertension has been characterized for 193 children through 
16 studies and 28 case series and reports. The primary efficacy data suggest that sildenafil is beneficial for 
facilitating the weaning of inhaled nitric oxide in children after cardiac surgery. Compiled safety data 
suggest that sildenafil is well tolerated among children with idiopathic pulmonary arterial hypertension 
and pulmonary arterial hypertension associated with congenital heart disease. This review summarizes the 
available data describing the use, safety, and efficacy of sildenafil for children with pulmonary 
hypertension. 
 
Idiopathic pulmonary arterial hypertension (IPAH) was first described by Romberg [66] more 
than 100 years ago as “sclerosis of the pulmonary arteries.” In recent decades, growing interest 
and advanced research in pulmonary hypertension (PHTN) has led to a better understanding of 
the disease process. A rare condition, PHTN is characterized by a progressive increase in 
pulmonary vascular resistance leading to right ventricular failure and premature death [21]. 
Often, PHTN is associated with underlying conditions such as congenital heart disease, 
connective tissue disease, congenital diaphragmatic hernia, and others. When PHTN is present in 
conjunction with these processes, it is referred to as associated pulmonary arterial hypertension 
(APAH). Previously referred to as primary pulmonary hypertension, IPAH is defined as PHTN 
in which the underlying cause is unknown or of sporadic onset [67]. Although the true incidence 
of IPAH is unknown, it is estimated to occur in one to two cases per million people [81]. 
In the early 1980s, before the development of our current and more advanced treatment methods, 
the Primary Pulmonary Hypertension NIH Registry reported a median survival time of 2.8 years 
after a diagnosis of PHTN for adults but only 10 months for children [17]. Whereas the historical 
prognosis of a patient with PHTN had been very poor, significant advances in early diagnosis 
and advanced treatment options not only have extended survival but also have improved quality 
of life, exercise capacity, and hemodynamics [7, 32, 65]. 
A recent United Kingdom treatment and survival study reviewed 216 patients with PHTN and 
found survival rates of 85.6% at 1 year, 79.9% at 3 years, and 71.9% at 5 years for patients with 
IPAH and 92.3% at 1 year, 83.8% at 3 years, and 56.9% at 5 years for patients with APAH. The 
prolonged survival found in this study can be attributed in part to advancements in 
pharmacologic treatment options including epoprostenol, bosentan, and sildenafil [31]. 
To date, sildenafil has been the most studied phosphodiesterase 5 (PDE-5) inhibitor and the most 
widely used treatment option among pediatric patients with PHTN. The available information 
supporting the use of sildenafil for pediatric PHTN is growing. Since the first reports describing 
the use of sildenafil for children, clinicians have continued to gain experience and have 
contributed further to the availability of safety and efficacy data through small, uncontrolled 
trials [6, 23, 36, 45, 49, 52, 55, 58–60, 62, 63, 69, 72, 75, 77], published reviews [3, 16, 34, 51], 
and uncontrolled case reports [1, 2, 4, 5, 8–10, 12, 14, 18, 20, 24, 29, 30, 37–42, 44, 46–48, 54, 
56, 70, 82]. This article aims to review the available safety and efficacy data regarding sildenafil 
for the treatment of PHTN in pediatric patients. 
 
Pediatric PHTN 
Definition 
The diagnostic classification of PHTN was revised at the 2003 World Pulmonary Hypertension 
Symposium and reflects new understanding of the disease [73]. Unlike adults, children most 
often present with APAH secondary to other pathologies, with IPAH being much less common. 
Frequent causes of PHTN in children include congenital cardiac and vascular disease, chronic 
lung disease, persistent PHTN of the newborn, and metabolic and genetic factors [73]. 
 
Pulmonary hypertension has been defined as a mean pulmonary artery pressure (PAP) of 
25 mmHg or more at rest and 30 mmHg or more with exercise, in conjunction with a pulmonary 
vascular resistance of 3 Woods units/m
2
 or more and a normal pulmonary artery wedge pressure 
of 15 mmHg or less [67]. Although this definition is the same for both adults and children, the 
disease process often is very different within the pediatric population. Whereas adults typically 
present with a diminished cardiac index, the cardiac index of children often is normal at 
presentation [67]. Additionally, exercise hemodynamic abnormalities appear to be amplified in 
pediatric patients due to diminished vasoactive responses. Normally, the pulmonary vascular bed 
has the ability to accommodate for increases in blood flow during exercise via vasodilation and 
recruitment of unused vasculature. This capacity is lost with PHTN, resulting in further 
elevations in pulmonary artery pressure with exercise. The inability to increase cardiac output in 
response to increases in oxygen demand can manifest as dyspnea and syncope. Exertional and 
postexertional syncopal episodes occur more commonly with children, manifesting this lack of 
compensation in cardiac output and resulting in diminished cerebral blood flow. 
Pathophysiology of PHTN 
Irrespective of the etiology of PHTN, pathophysiologic alterations are common among all types. 
The principal mechanism of PHTN is a combination of vasoconstriction, vascular remodeling, 
and thrombus formation within the pulmonary vasculature. Advanced pathophysiologic studies 
have identified vasoconstriction and vascular remodeling associated with endothelial dysfunction 
as playing a key role in the development of PHTN [35]. Extensive animal and human models 
have established the role of endogenous nitric oxide (NO) and the cyclic guanosine 
monophosphate (cGMP) signaling pathway in the regulation of pulmonary vasodilation. 
Endogenous NO activates soluble guanylate cyclase, which in turn increases intracellular cGMP. 
Interactions between cGMP and cGMP-dependent protein kinases subsequently result in 
vasodilation [43]. Further understanding of this pathway has led to clinically important treatment 
options including inhaled NO (iNO) administration and drugs such as sildenafil that inhibit 
metabolism of cGMP. 
Congenital heart defects causing increased pulmonary blood flow (often via left-to-right 
shunting), pulmonary vein obstruction, and cyanosis are most likely to be associated with PHTN. 
Many surgeries for congenital heart disease require the use of cardiopulmonary bypass. A study 
of pediatric patients after cardiopulmonary bypass has demonstrated an association with 
temporary pulmonary endothelial dysfunction and suppression of endogenous NO production 
[13]. Additionally, the systemic inflammatory response to cardiopulmonary bypass is associated 
with increased production of endothelin, a potent pulmonary vasoconstrictor [13, 71, 80]. 
Further confounding the general pathophysiologic process of PHTN is the impact of iNO. 
Children born with total anomalous pulmonary venous connection, transposition of the great 
arteries, large ventricular septal defects, and atrioventricular canal are at significant risk for both 
pre- and postoperative PHTN [71, 80]. These children may be managed preoperatively with iNO, 
and treatment often is continued for postoperative PHTN. The presence of exogenous or inhaled 
NO has been associated with a downregulation of endothelial NO synthase. Prolonged impaired 
production of vasoactive mediators such as NO and prostacyclin and overexpression of 
vasoconstrictors such as endothelin-1 lead to changes in vascular tone and pulmonary arterial 
smooth muscle hypertrophy [15, 26, 27, 35]. All these factors contribute to the risk of PHTN 
development in children with significant congenital heart disease after surgical repair. 
Treatment Options 
Currently, no pharmacologic cure exists for PHTN. Treatment is aimed at relieving symptoms 
and slowing disease progression. Fewer than 10 years ago, management of infants and children 
with PHTN was limited to aggressive ventilator strategies and iNO for critically ill inpatients, 
whereas outpatients were treated with calcium-channel blockers, anticoagulation, and continuous 
infusions of intravenous (IV) epoprostenol [79]. Subsequent clinical trials demonstrated the 
therapeutic efficacy of endothelin-receptor blockers and aerosolized prostacyclins and their 
analogs [33]. Because of serious side effects, complicated administration techniques, and 
difficulty obtaining these medications, the application of these treatment options often is limited 
to specialized PHTN treatment centers [33]. 
Sildenafil for PHTN 
Mechanism of Action/Pharmacology 
Sildenafil is a phosphodiesterase inhibitor with high selectivity against isoform 5. Expression of 
PDE-5, located largely in pulmonary vascular smooth muscle, is responsible for the breakdown 
of cGMP to guanosine 3′-cyclic phosphate (5′-GMP). Thus, inhibition of PDE-5 results in an 
increased endothelial level of cGMP and vascular smooth muscle relaxation. Pharmacotherapy 
with PDE-5 inhibitors, such as sildenafil, is a rational treatment option given the endothelial cell 
dysfunction and vasoconstriction within the pulmonary vasculature that contribute to PHTN. 
This specific mechanism of sildenafil action also makes it an ideal drug to consider for weaning 
iNO, as discussed later in this review. 
Pharmacokinetics 
The pharmacokinetic and metabolic profiles of sildenafil are based on studies with adult patients 
of varying ages, genders, races, and renal and hepatic functions [64]. The pharmacokinetics and 
pharmacodynamics of sildenafil in children with PHTN have not been studied to date. Sildenafil 
is absorbed rapidly, with onset of action in 30–120 min (mean, 60 min) for a fasting patient. 
When given in combination with fatty meals, the time to onset is delayed an additional 60 min, 
and the achieved peak concentration is reduced by 29% due to decreased absorption [64]. 
Sildenafil undergoes extensive first-pass metabolism, and the oral bioavailability is 40%. Hepatic 
metabolism is via cytochrome P (CYP) 3A4 (major) and CYP 2C9 (minor) into active 
metabolites. The active metabolite N-desmethyl sildenafil makes up 40% of serum 
concentrations and is responsible for 20% of the pharmacologic activity [64]. Both sildenafil and 
N-desmethyl sildenafil are approximately 96% plasma protein bound, with terminal half-lives of 
approximately 4 h. Sildenafil is eliminated as metabolites primarily in the feces (approximately 
80% of the administered dose), with approximately 13% excreted in the urine [64]. 
Drug Interactions 
Because metabolism of sildenafil is mostly via CYP 3A4 and to a lesser extent via CYP 2C9, any 
inhibitor or inducer of these enzymes may potentially alter the clearance of sildenafil. Ritonavir, 
ketoconazole, itraconazole, and other potent CYP 3A4 inhibitors as well as other nonspecific 
CYP inhibitors given concomitantly are associated with increases in sildenafil plasma levels 
[64]. Fluconazole, a drug commonly used for children, moderately inhibits CYP 3A4. The 
pharmacologic effects of sildenafil are potentially increased when it is used in combination with 
fluconazole or any of the other CYP inhibitors. One case report in the literature describes the 
safe use of fluconazole and sildenafil concomitantly in an infant [19]. 
Bosentan, a CYP 3A4 and 2C9 inducer, given in conjunction with sildenafil causes a decrease in 
sildenafil plasma concentrations. Interestingly, this drug combination can be characterized as a 
mutual pharmacokinetic interaction due to the simultaneous decrease in sildenafil and increase in 
bosentan concentrations. In one study, sildenafil plasma concentrations were monitored in 
healthy volunteers given sildenafil 80 mg three times daily and bosentan 125 mg twice daily 
[61]. The sildenafil dose-interval area under the curve (AUC) was shown to decrease as much as 
62.6% and the bosentan dose-interval AUC to increase as much as 49.8% [11]. 
In a study of 10 patients with PHTN, a 50% reduction in sildenafil AUC was noted after a single 
100-mg dose in conjunction with bosentan 62.5 mg twice daily. This small study found the 
combination of sildenafil and bosentan to be safe and effective. Because clinical data on the use 
of sildenafil and bosentan in combination are minimal, no current recommendations exist for 
adjusting doses of either drug. Caution is warranted when the agents are used simultaneously 
[64]. 
Dosage and Administration Considerations 
In the United States, sildenafil is available only in oral tablet formulation at select strengths 
(Revatio 20 mg; Viagra 25, 50, and 100 mg). To obtain patient-specific weight-based dosages in 
a more child-friendly preparation, an oral solution of sildenafil can be extemporaneously 
compounded [57]. The stability of a compounded suspension has been validated for up to 
91 days at temperatures of 4°C and 25°C [57]. Notably, this specific formulation was developed 
using the Viagra dosage form. Compounding data for the Revatio dosing form are not available. 
Because Revatio is the Food and Drug Administration (FDA)-approved sildenafil dosage form 
for PHTN, the potential exists for issues with medical insurance reimbursement for liquid 
formulations prepared using a non–FDA-approved sildenafil form. 
Sildenafil Efficacy 
Sildenafil was first FDA approved in 2005 for the treatment of adult patients with PHTN after 
the results from SUPER-1, a large, multinational placebo-controlled trial [21]. Numerous clinical 
studies have demonstrated the efficacy of sildenafil for adults with PHTN, but few studies have 
evaluated the efficacy of sildenafil for children (Table 2). Total pediatric efficacy data, available 
through prospective and retrospective studies as well as observational reports, include 193 
infants and children with both IPAH and APAH. Of these, the retrospective and prospective 
studies account for approximately 80% of the efficacy data and include 156 children. 
 
 
Table 2 Sildenafil efficacy 
Study, design n  Age (years) Dosage/route Indication 
Treatment 
duration 
Outcomes 
Peiravian [62], 
RCT 
20 1–16 
Oral: 0.3 mg/kg 
q3 h 
PHTN–CHD: 
VSD, PDA, 
ASD, APW, 
SAW 
24–48 h 
Improved postoperative 
PAP and PA/Ao 
Namachivayam 
[58], RCT 
15 0.1–1.31 
Oral: 0.3–
0.5 mg/kg 
All patients 
intubated, 
sedated, on iNO 
1 dose 
Successful wean off iNO; 
no rebound PHTN 
(P  <  0.001); reduced 
elevation of PAP 
mechanical ventilation: 
28.2 vs. 137 h in sildenafil 
vs. placebo groups 
(P = 0.024); total ICU stay: 
47.8 vs. 189 h in sildenafil 
vs. placebo groups (P = 
0.004) 
Baquero [6], 
RCT 
7 
>35.5 weeks 
gestation & 
<3 days 
Enteral: 1–
2 mg/kg q6 h 
PPHN 36 h 
Improved oxygenation 
index (P < 0.05); improved 
pulse oxygen saturation (P 
< 0.05) 
Raposo-
Sonnenfeld 
[63], PT 
9 1–17 yr 
Oral: 1 – 2 mg/kg 
divided TID 
Group A: IPAH, 
PHTN–CHD 
Group B: ES plus 
CHD with 
nonrestrictive 
VSD 
2 years 
Improved exercise capacity 
(6-MWD); improved 
functional class 
Study, design n  Age (years) Dosage/route Indication 
Treatment 
duration 
Outcomes 
Humpl [36], PT 14 5.3–18 
Oral: 0.25–
1 mg/kg 4 × daily 
IPAH, PHTN–
CHD s/p repair, 
PFO 
6–15.3 
months 
Improved 6-MWD; 
improved hemodynamics 
Oliveira [59], 
PT 
6 3–19 
Oral: 2–
8 mg/kg/day or 
100–500 mg/day 
(4–6 doses/day) 
IPAH 4–36 months 
Improved functional class; 
improved systemic 
saturation 
Stocker [77], 
PT 
15 0.11–0.7 
IV: 0.35 mg/kg × 
1 dose, before or 
after iNO 
PHTN–CHD s/p 
VSD or ASD 
defect 
repair/closure; 
stable patients at 
risk of PHTN 
1 dose 
Improved hemodynamics; 
SBP decreased 
significantly (P < 0.05); 
sildenafil-augmented 
pulmonary vasodilator 
effects of iNO 
Schulze-Neick 
[72], PT 
12 0.11–15.7 
IV: In cath, 0.33 
and 0.66 mg/kg; 
postop, 0.025, 
0.1, and 
0.25 mg/kg 
Increased PVR, 
CHD 
2 or 3 doses 
Improved hemodynamics; 
increased intrapulmonary 
shunting (P = 0.04) 
Kothari [45], 
PT 
9 5–18 
Oral: 
5.5 mg/kg/day–
150 mg/day TID 
IPAH, PHTN–
CHD s/p repair 
3.5–8 
months 
Improved NYHA 
functional class; improved 
6-MWD; improved 
hemodynamics 
Sastry [69], PT 7 4–16 
Oral: 25–100 mg 
q8 h 
IPAH 5–20 months 
Improved functional class; 
improved 6-MWD; 
improved hemodynamics 
Otero Gonzalez 
[60], OS 
2 12 and 15 
Oral: 25 mg q8 h, 
increased to 
50 mg q8 h 
IPAH 12 months 
Improved exercise 
tolerance (6-MWD); 
improved functional class 
Lunze [52], OS 8 5.5–17.5 
Oral: 1.2–3 mg/kg 
3–4 times daily 
IPAH, PHTN–
CHD 
Combination 
therapy with 
bosentan 
0.4–
2.5 years 
Improved oxygen 
saturation; improved 6-
MWD and mean PAP 
Mourani [55], 
RS 
25 14–673 days 
(mean, 
Oral: 1.5–
8.0 mg/kg/day 
Chronic lung 
disease 
Mean 
duration, 
241 days 
Improved hemodynamics 
Study, design n  Age (years) Dosage/route Indication 
Treatment 
duration 
Outcomes 
171 days) (range, 28–
950 days) 
Lee [49], RS 7 
3 days–21 
months 
(median, 12 
months) 
0.22–0.47 mg/kg 
4 times daily 
Patient with 
previous failed 
wean from iNO, 
PAH–CHD 
Mean 
duration, 
28 days 
No rebound with sildenafil; 
mean time to iNO 
discontinuation 4.4 days 
after sildenafil; reduced 
iNO requirement after 
sildenafil initiation (P = 
0.024); facilitated wean off 
iNO 
 
The pediatric studies have included patients with PHTN of various etiologies. Eight prospective studies, 
including a series of 87 children (ages ranging from infancy to 19 years) taking oral sildenafil, describe 
sildenafil’s efficacy for improving hemodynamics and exercise tolerance [6, 36, 45, 58, 59, 62, 63, 69]. 
Three of the prospective studies were randomized controlled trials involving pediatric patients with either 
persistent PHTN of the newborn or PHTN related to congenital heart disease [6, 58, 62]. Sildenafil 
improved the oxygenation index (calculated as fraction of inspired oxygen × mean airway 
pressure/arterial partial pressure of oxygen) compared with baseline and placebo values for seven infants 
within 6–30 h after initiation of treatment [6]. Significant improvements in oxygen saturation also were 
observed in the sildenafil-treated infants compared with baseline and placebo values (P < 0.05). Sildenafil 
was shown to decrease postoperative systolic PAP significantly compared with the PAP of placebo-
treated children [62]. An important measure of PHTN severity is the ratio of PAP to aortic pressure, 
which was significantly lower with sildenafil than with placebo (P = 0.001). Effective doses of sildenafil 
in these prospective studies ranged from 0.3 to 8 mg/kg/day [6, 58, 62]. 
Inhaled Nitric Oxide Weaning 
Many children are benefited by the use of iNO, but the downregulation of endothelial NO can 
make it difficult to wean patients from iNO in a timely fashion. For this reason, iNO typically is 
weaned slowly and not stopped abruptly in the clinical setting. Rebound PHTN, presenting as an 
acute increase in PAP and cardiopulmonary instability, can complicate the withdrawal of iNO. 
Two small studies [49, 58] in addition to several case reports [4, 5, 42, 70] have identified 
sildenafil as a means for minimizing rebound PHTN and the need for prolonged iNO therapy. 
Namachivayam et al. [58] demonstrated sildenafil’s efficacy to facilitate iNO weaning of 29 
infants and children. In this study, clinical rebound PHTN was defined as an increase of 20% or 
more in PAP or failure to discontinue iNO. None of the 15 sildenafil-treated patients (0.4 mg/kg 
times 1 dose) experienced clinical rebound PHTN, and all 15 were successfully weaned from 
iNO. Of 14 placebo-treated patients, 10 did experience clinical rebound PHTN (P < 0.001), with 
4 of them failing to be weaned from iNO. Mean PAP increased by 1% in the sildenafil group and 
25% in the placebo group at withdrawal of iNO (P < 0.001) [58]. 
A recent study by Lee et al. [49] examined seven children with congenital heart disease who 
previously had failed iNO weaning attempts before the initiation of oral sildenafil (0.22–
0.47 mg/kg 4 times daily). Treatment with sildenafil significantly reduced iNO requirements 
within 24 h and facilitated iNO weaning for all seven patients [49]. Case reports describe similar 
observations [4, 5, 56, 70]. Reported effective doses of sildenafil used to assist in weaning iNO 
ranged from 0.2 to 1 mg/kg/dose (average, 0.5 mg/kg/dose) administered once or up to every 4–
6 h. 
Long-Term Outpatient Therapy 
Inpatient sildenafil use has been widely adopted in pediatric hospitals, and this has encouraged 
the growth of outpatient sildenafil use. Long-term or chronic sildenafil administration for PHTN 
is becoming common despite the limited efficacy of this type of therapy for children. In 2005, 
Humpl et al. [36] published an open-label, single-drug pilot study of 14 outpatients with IPAH, 
PHTN secondary to congenital heart disease, or Eisenmenger syndrome. At the 12-month 
follow-up assessment, the patients demonstrated sustained benefit in exercise tolerance, as 
measured by the 6-min walk distance of 278 ± 114–432 ± 156 m (P = 0.005). Improvements 
were shown in hemodynamic parameters through a mean PAP reduction from a median of 
60 mmHg to a median of 50 mmHg (P = 0.014) and a median pulmonary vascular resistance 
decrease from 15 to 12 Woods units/m
2
 (P = 0.024). 
Raposo-Sonnenfeld et al. [63] studied 10 children with IPAH (n = 5) or PHTN associated with 
congenital heart disease (n = 5) treated with sildenafil for a minimum of 2 years. The patients 
treated with sildenafil showed significant improvement in exercise capacity and World Health 
Organization functional classification. This was most notable for the patients with IPAH. In this 
group, the 6-min walk distance improved from 394.2 ± 55.2 m at baseline to 526.7 ± 44.6 m at 
2 years. The functional classification of patients with IPAH improved for six of seven patients in 
class 3 or 4 at baseline and for no patients in class 3 or 4 at 2 years. Side effects were minimal, 
consisting menorrhagia experienced by two female patients, ages 11 and 12 years. The 
symptoms resolved after regulation of the patients’ menstruation and treatment of their anemia 
[63]. 
Mourani et al. [55] reviewed 25 patients younger than 2 years with chronic lung disease who 
were being treated with sildenafil for the management of PHTN. The patients were treated a 
median of 241 days (range, 28–950 days), with 88% of the patients achieving hemodynamic 
improvement after a median of 40 days. Hemodynamic improvement in this study was defined as 
a 20% decrease or more in the ratio of pulmonary to systemic systolic arterial pressure or 
improvement in the degree of ventricular septal flattening on serial echocardiograms. Sildenafil 
was well tolerated in this group. One patient discontinued therapy after 950 days due to frequent 
erections. Another patient’s therapy was briefly interrupted due to intestinal pneumatosis. During 
the follow-up period, five patients died: one of sepsis and the remaining four when support was 
withdrawn due to respiratory futility (n = 3) or neurologic devastation (n = 1). In each of these 
five patients, progressive improvement in PHTN had been demonstrated through serial 
echocardiographic assessments, and none of the deaths were the result of refractory PHTN or 
right heart failure. 
Sildenafil Combination Therapy 
For patients whose treatment with monotherapy has been ineffective, combination therapy can be 
used. Recent published adult data have shown successes with combination therapy [25, 28, 68, 
74, 78]. Evidence for pediatrics, however, still is lacking. Successful use of prostaglandin E1, 
iNO, and sildenafil was described for an infant with congenital diaphragmatic hernia, with 
oxygen saturation improved from 60 to 90% within 24 h. The patient showed continued 
improvement, with uneventful discontinuation of iNO at 4 days and prostaglandin E1 at 8 days. 
This patient was discharged home after 54 days of therapy, with sildenafil discontinued [20]. No 
additional published data describing this combination for children are available. 
Bosentan and sildenafil have demonstrated efficacy individually for managing various forms of 
PHTN, but again, few studies characterize their combined use for children. A 2007 observational 
study included eight children with PHTN related to congenital heart disease who were treated 
with bosentan and sildenafil. This combination brought about significant improvement in 
functional class (mean, 2.8 ± 0.4 to 1.6 ± 0.8; P = 0.001). Improvements also were seen in 
oxygen saturation (89.9 ± 9.9% to 92.3 ± 7.1%; P = 0.037), 6-min walk distance (351 ± 58 to 
451 ± 119 m; P = 0.039) and mean PAP (62 ± 12 to 46 ± 18 mmHg; P = 0.041) [52]. 
Combination therapy using sildenafil and bosentan as an oral treatment alternative to IV 
prostacyclin therapy offers potential benefit. Brancaccio et al. [9] reported successful 
discontinuation of IV prostacyclin without the need for reinitiation at the 4-year follow-up 
assessment when combination bosentan and sildenafil was used with a 7-year-old. Although 
combination therapy has anecdotally proved to be a benefit for a few patients, additional larger 
studies are needed to address the use of combination therapy as a more effective alternative to 
monotherapy. 
 
Sildenafil Safety 
The adverse event profile observed and reported for the adult population depicts sildenafil as a 
generally safe and well-tolerated medication. In the SUPER-1 trial, the most frequent adverse 
events observed with the FDA-approved dosage of 20 mg orally 3 times daily included epistaxis 
(8%), headache (7%), dyspepsia (6%), insomnia (6%), and flushing (6%) [21]. At doses 
exceeding the FDA-approved doses, the incidence of flushing, myalgia, diarrhea, and visual 
disturbances (described as color-tinged vision, increased sensitivity to light, and blurred vision) 
are increased [21]. In comparison, the limited pediatric data available show a parallel among 
adverse events reported. Table 3 summarizes the adverse events noted in pediatric studies and 
case reports. 
 
 
Table 3 Adverse events  
Adverse event Description n  
Incidence 
(%)
a
  
Hypotension [37, 49, Significant blood pressure reduction and impaired oxygenation 
15 5.9 
Adverse event Description n  
Incidence 
(%)
a
  
77] with IV, transient with PO 
Erection [12, 55, 62] Mostly short-lived erection, one recurrent 6 2.6 
Nasal congestion [60, 
62] 
Transient, resolved upon discontinuation (5) 6 2.3 
Headache [23, 36, 45, 
60, 69] 
Persistent (sildenafil suspended 4 mo) One only with dose 
>125 mg 
4 1.6 
Dizziness [36, 45] Resolved with dose reduction; one only with dose >125 mg 3 1.2 
Flushing [36, 45, 69] Resolved with dose reduction; one only with dose >125 mg 3 1. 2 
Bleeding [22] 
Circumferential oozing after circumcision requiring 
cauterization and sutures; penis was erect 
1 <1 
Body ache [23] Mild, self-limiting 1 <1 
Epistaxis [36] Self-limiting 2 <1 
GI upset [62] Not otherwise described 2 <1 
Heavy menstrual flow 
[36] 
With menarche, responded to progesterone therapy 2 <1 
Optic neuropathy [76] Monocular visual loss 1 <1 
Pneumothorax [18] Questioned relatedness 1 <1 
Retinopathy [53] Retinopathy of prematurity 1 <1 
Rhinorrhea [23] Resolved with dose reduction 2 <1 
Intestinal pneumatosis 
[55] 
Temporarily discontinued, safely restarted without other 
documented adverse event (continued 688 days) 
1 <1 
Abdominal 
discomfort [69] 
Not otherwise described NR   
 
For this review, the incidence of each reported adverse event was calculated using the sum of all 
the patients receiving sildenafil in the studies and case reports. All the studies and case reports 
made reference to adverse events, often noting that no event was experienced, although few 
investigations specifically stated how or which adverse events were monitored. The calculated 
incidences of these adverse events are low, but this may be a reflection of the limited reporting 
within published data. Thus, the lack of toxicities from the available data may not necessarily 
reflect the general safety of the drug, and continued prudent use is warranted. 
A notable concern with sildenafil is the risk for optic changes including visual disturbances, 
retinal hemorrhage, and optic neuropathy. The color-tinged vision experienced by some patients 
is the result of sildenafil’s effect on phosphodiesterase-6, resulting in an alteration of the GMP 
level in the retina [76]. In the SUPER-1 trial, the incidence of retinal hemorrhage was 1.4% of 
patients receiving the recommended treatment dose of 20 mg orally 3 times daily (1.9% for all 
groups) compared with 0% of patients receiving a placebo [21]. Notably, most of these patients 
were concomitantly receiving anticoagulation therapy, increasing the risk of bleeding. Only 
minimal pediatric data support an association of retinal hemorrhage with sildenafil use. Two case 
reports describe ischemic optic neuropathy in a 6-year-old and retinopathy of prematurity in a 
26-week-gestation neonate loosely correlating with the use of sildenafil [53, 76]. The nonspecific 
temporal association and the multitude of potential alternate causes, especially the risk of 
retinopathy for a premature neonate, limits conclusions of a causal relationship. To date, no 
strong evidence has associated sildenafil with retinal or choroidal blood changes in children. 
 
Intravenous Sildenafil 
Sildenafil is available as an IV injection in various countries outside the United States, but 
available data on use of the IV form for children are limited. Lammers et al. [48] reported the 
successful use of IV sildenafil for a 7-month-old with known PHTN in acute respiratory failure 
after an episode of aspiration. Oral sildenafil was changed to an IV infusion of 0.3 mg/kg/min 
due to perceived ineffective absorption. The change resulted in stabilization of the patient’s 
clinical condition without a reduction in systemic arterial pressure or an increased need for 
inotropic support throughout the duration of the sildenafil infusion. 
Stocker et al. [77] studied the acute effects of IV sildenafil and its interaction with iNO on 
hemodynamics and oxygenation for 15 infants at risk for PHTN after cardiac surgery. 
Intravenous sildenafil was shown to augment the beneficial pulmonary vasodilatory effects of 
iNO, as evident by reductions in the pulmonary vascular resistance index from 2.95 to 2.45 U (P 
< 0.05) when iNO was given before sildenafil. For patients receiving sildenafil first, the 
pulmonary vascular resistance index decreased from 2.84 to 2.35 U (P < 0.05). However, 
sildenafil treatment also resulted in a significantly reduced systemic blood pressure and systemic 
vascular resistance (P < 0.01) in both groups. Infants receiving sildenafil in this study also 
experienced worsened arterial oxygenation and alveolar–arterial gradient (P < 0.05). The study 
was terminated early due to the significant reduction in systemic blood pressure and deterioration 
in oxygenation, which did not improve with iNO. 
Schulze-Neick et al. [72] observed similar results among 24 patients treated with IV sildenafil 
either during cardiac catheterization or within 2 h after cardiac surgery. Pulmonary vascular 
resistance was reduced more effectively with sildenafil than with iNO (11.5% vs. 4.3% in the 
catheterized patient group [P < 0.05] and 25.8% vs. 14.6% in the postoperative patient group [P 
= 0.09]). Sildenafil also was noted to potentiate a cGMP increase in response to iNO. Neither 
treatment with iNO nor the infusion of sildenafil alone significantly increased plasma cGMP 
levels, but cGMP levels increased when treatment therapies were combined (P < 0.001). 
Increased intrapulmonary shunting in patients receiving IV sildenafil postoperatively compared 
with patients receiving iNO (P = 0.04) further supports the safety concerns with this dosage 
form. 
The observed problems of systemic hypotension and impaired oxygenation experienced by 
patients receiving IV sildenafil raise concerns and could limit its use if it were to become 
available in the United States. Further studies evaluating the pharmacokinetics of IV sildenafil 
with children to explore therapeutic effects and toxicities related to IV administration are 
warranted. 
Pharmacoeconomic Consideration 
The development of advanced treatment methods for the management of PHTN has led to a 
growing financial implication for both patients and the institutions caring for these patients. 
Special considerations including extemporaneous compounding and complex delivery systems 
further add to the staggering cost of long-term pharmacologic management of the disease. 
Table 4 outlines a cost comparison of pharmacologic treatment options for chronic PHTN 
management. Compared with alternative treatment options, sildenafil appears to be an affordable 
option. Based on average wholesale price, a typical 1-month supply of bosentan, epoprostenol, 
and inhaled iloprost for a 10-kg patient would easily total more than $2,000 for each. For that 
same 10-kg patient, a sildenafil compounded solution would cost a fraction of that, at $330 for a 
1-month supply. This treatment option could save the patients and caregivers thousands of 
dollars annually. 
 
Table 4 Outpatient considerations 
Drug 
Cost per 30-day 
supply (average 
doses for 10-kg 
patient) 
Special considerations Special access 
Sildenafil 
(Revatio,Viagra) 
$329.99
a
 
(1 mg/kg/dose PO 
TID 480 ml) 
Compounded
b
  
Available at compounding 
pharmacies 
Bosentan 
(Tracleer) 
$2,436.00
c
 
(31.25 mg PO BID 
62.5 mg 30 tablets) 
Liquid not available; 
preparation before 
administration 
Tracleer Access Program 
(TAP) enrollment 
required; access through 
specialty distributors 
Epoprostenol 
(Flolan) 
$2,287.20
c
 (includes 
diluents) (0.5 mg 
vial × 20, 50-mL 
diluents × 60) 
Administered through a 
central venous line; 
requires cooling to between 
2º and 8°C; special diluents 
for reconstitution 
Available only through 
Accredo specialty 
pharmacy 
Excludes cost for 
Drug 
Cost per 30-day 
supply (average 
doses for 10-kg 
patient) 
Special considerations Special access 
CVL maintenance + 
home nursing + cold 
packs 
Inhaled iloprost 
(Ventavis) 
$8,823.60
c
 (30 × 6 
of 10 μg/ml) (based 
on 5 μg inhaled 6 × 
day) 
Ventavis I-neb AAD 
system 
PAH Pathways (Actelion) 
enrollment program; 
requires specialty 
pharmacies; Sure Steps 
patient education program 
optional 
 
Sildenafil often is used within the hospital inpatient setting, especially in conjunction with iNO. 
Namachivayam et al. [58] identified sildenafil not only as a means for preventing rebound PHTN, but also 
as a potential for cost savings. The duration of mechanical ventilation averaged 28.2 h for the 15 patients 
treated with sildenafil and 98 h for the 14 patients treated with placebo (P = 0.024). The total intensive 
care unit length of stay after study completion was reduced from a mean of 189 h for the placebo group to 
47.8 h for the sildenafil group (P = 0.004) [58]. By affording patients an average of nearly 3 days less on 
the ventilator and an average shortened intensive care unit stay of 6 days, there is a potential for 
substantial cost savings to both the hospital and the patient. Future pharmacoeconomic studies are needed 
for further evaluation of these financial implications. 
Conclusions 
Significant advances in early diagnosis and advanced pharmacologic treatment options for 
pediatric PHTN not only have extended survival but also have improved quality of life, exercise 
capacity, and hemodynamics [7, 32, 65]. With improved understanding of the pathophysiology 
of PHTN, novel pharmacologic agents inhibiting PDE-5, such as sildenafil, have been developed 
and quickly have become favored therapeutic options. Efficacy data from small case series, case 
reports, and small uncontrolled trials support the use of sildenafil. Although a wide range of 
doses were given in case reports and trials, the most-used effective dosing regimen ranges from 
0.5 to 2 mg/kg given three times daily to a maximum dose of about 8 mg/kg/day. To confirm the 
overall safety and efficacy of sildenafil for the treatment of PHTN in the pediatric population, 
large-scale randomized, controlled trials are warranted. 
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